N7161

Nogo-66(1-40) antagonist peptide

≥84% (HPLC), Nogo-66 blocker, lyophilized solid

• Sinónimos: NEP (1-40)
• Fórmula empírica (notación de Hill): C₂₀₄H₃₂₂N₅₆O₆₄ · xC₂HF₃O₂
• Peso molecular: 4583.08 (free base basis)
• UNSPSC Code: 12352202
• NACRES: NA.32
• MDL number: MFCD06411437

Propiedades

• Nombre del producto: Nogo-66(1-40) antagonist peptide, ≥84% (HPLC)
• assay: ≥84% (HPLC)
• form: lyophilized solid
• color: white
• solubility: H₂O: 1 mg/mL
• UniProt accession no.: Q9NQC3
• storage temp.: −20°C
• SMILES string: [nH]1cnc(c1)C[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CCCNC(=N)N)[C@H](CC)C)Cc6ccc(cc6
• InChI: 1S/C206H324N56O65/c1-23-104(15)163(258-169(292)109(20)226-174(297)126(59-67-148(210)272)240-201(324)166(107(18)26-4)261-199(322)160(101(9)10)255-153(277)92-223-171(294)120(41-30-33-75-207)230-186(309)138(86-115-51-57-119(271)58-52-115)249-202(325)165(106(
• InChI key: OLEKMOOQFWTQGD-SJQNMCRDSA-N
• Gene Information: human ... RTN4(57142)

Descripción

Application

Nogo-66(1-40) antagonist peptide has been used as a Nogo-66 receptor antagonist peptide:

• to study the preliminary therapeutic effect after inhibition of Nogo-A in the cauda equina compression (CEC) model[1]
• to determine the effects of Nogo-A/NgR1 on autophagic activation[2]
• to study its role in Nogo-B mediated axonal branching using Schwann cells and sensory neurons of mice[3]

Biochem/physiol Actions

Myelin-derived axon outgrowth inhibitors, such as Nogo, may account for the lack of axonal regeneration in the central nervous system (CNS) after trauma in adult mammals. Nogo-66 can inhibit axonal outgrowth through an axonal Nogo-66 receptor (NgR). Competitive antagonists of NgR derived from amino-terminal peptide fragments of Nogo-66. The Nogo-66(1 40) antagonist peptide (NEP1 40) blocks Nogo-66 or CNS myelin inhibition of axonal outgrowth in vitro, demonstrating that NgR mediates a significant portion of axonal outgrowth inhibition by myelin. Intrathecal administration of NEP1 40 to rats with mid-thoracic spinal cord hemisection results in significant axon growth of the corticospinal tract, and improves functional recovery. Thus, Nogo-66 and NgR have central roles in limiting axonal regeneration after CNS injury, and NEP1-40 provides a potential therapeutic agent.

Nogo-66(1-40) promotes axonal regeneration; it blocks effects of axon outgrowth inhibitors such as Nogo66.

Legal Information

Sold under a non-exclusive license. For research use only, and not for diagnostic or therapeutic use or for use in humans.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)